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Abstract
Background: Selection of hepatitis B virus (HBV) by host immunity has been suggested to give rise to variants
with amino acid substitutions at or around the ’a’ determinant of the surface antigen (HBsAg), the main target of
antibody neutralization and diagnostic assays. However, there have never been successful attempts to provide
evidence for this hypothesis, partly because the 3 D structure of HBsAg molecules has not been determined.
Tertiary structure prediction of HBsAg solely from its primary amino acid sequence may reveal the molecular
energetic of the mutated proteins. We carried out this preliminary study to analyze the predicted HBsAg
conformation changes of HBV variants isolated from Indonesian blood donors undetectable by HBsAg assays and
its significance, compared to other previously-reported variants that were associated with diagnostic failure.
Results: Three HBV variants (T123A, M133L and T143M) and a wild type sequence were analyzed together with
frequently emerged variants T123N, M133I, M133T, M133V, and T143L. Based on the Jameson-Wolf algorithm for
calculating antigenic index, the first two amino acid substitutions resulted in slight changes in the antigenicity of
the ’a’ determinant, while all four of the comparative variants showed relatively more significant changes. In the
pattern T143M, changes in antigenic index were more significant, both in its coverage and magnitude, even when
compared to variant T143L. These data were also partially supported by the tertiary structure prediction, in which
the pattern T143M showed larger shift in the HBsAg second loop structure compared to the others.
Conclusions: Single amino acid substitutions within or near the ’a’ determinant of HBsAg may alter antigenicity
properties of variant HBsAg, which can be shown by both its antigenic index and predicted 3 D conformation.
Findings in this study emphasize the significance of variant T143M, the prevalent isolate with highest degree of
antigenicity changes found in Indonesian blood donors. This highlights the importance of evaluating the effects of
protein structure alterations on the sensitivity of screening methods being used in detection of ongoing HBV
infection, as well as the use of vaccines and immunoglobulin therapy in contributing to the selection of HBV
variants.
Background
Hepatitis B Virus (HBV), the etiology of hepatitis B, is a
DNA virus that replicates via an RNA intermediate [1].
It has a small partially double-stranded DNA genome of
approximately 3.2 kilobases that contains four overlap-
ping open reading frames, including one that encodes
for the hepatitis B surface antigen (HBsAg) protein [1].
Diagnosis and screening of HBV infection is most com-
monly done by detection of the HBsAg by means of
antibody-based assays [2]. These assays target the ‘a’
determinant, the highly homologous region within
HBsAg, which is also used as the main target of anti-
body generated by hepatitis B vaccines [2]. However,
there have been reports on the failure of these assays in
detecting HBsAg in infected individuals, which include
inactive HBV carriers, vaccinated children born to
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mothers with HBV infection, and liver transplant recipi-
ents treated with hepatitis B immunoglobulin (HBIg)
therapy [3-5].
Recognition of the ’a’ determinant by antibody against
HBsAg (anti-HBs) depends on its 3 D conformation,
which also relies on the amino acid sequence of the
regions flanking the ’a’ determinant [6,7]. To date, there
have never been successful attempts on crystallizing
native HBsAg molecules for structure determination
purposes. Tertiary structures of HBsAg have not been
fully determined, aside from its nature as a membrane
spanning protein with four trans-membrane helices and
a major hydrophilic region that is exposed on the sur-
face of the virus [7,8]. It is of interest to be able to pre-
dict the tertiary structure of HBsAg solely from its
primary amino acid sequence, because pathogen recog-
nition by the host immune system is mainly based on
protein-protein interaction, which depends on the con-
formation of the interacting proteins. We carried out
this preliminary study to analyze the prediction of
HBsAg conformation changes as caused by variations in
the S gene of HBV isolated from Indonesian HBsAg-
negative blood donors in comparison with variants fre-
quently reported from various regions of the world. The
results of this study may contribute in better under-
standing the host-pathogen interaction as well as paving
the way to develop better techniques in designing diag-
nostic tools and vaccine candidates for hepatitis B.
Materials and methods
Sample selection and preparation
This study is part of a larger project investigating the
main transfusion-transmitted infections including hepa-
titis B in regular blood donors by the Indonesian Red
Cross in two cities of Indonesia, Medan of Sumatra and
Solo of Java islands. Previous study by Thedja et al.,
2010 showed that HBV DNA was detected in 25 (8.1%)
of 309 HBsAg-negative blood donors [9]. HBV DNA in
the blood donors’ samples was undetectable by quantita-
tive PCR and detectable only in the second-round of
nested PCR, which was capable of detecting HBV DNA
at titres lower than the detection limit of the Cobas-
Taqman 48 Real-Time PCR (Roche Molecular System,
Branchburg, NJ, USA), 6 IU/mL [9,10]. The sequences
of HBV DNA isolated in the study had been deposited
in GenBank under Accession Nos. EF507434-EF507475
and HM116516-HM116533. To analyze the HBsAg
conformation changes resulted from variations in
the S gene, we first aligned the translated nucleotide
sequences of HBV isolated from the Indonesian HBsAg-
negative blood donors with a wild type reference
(M54923; genotype B/adw) retrieved from GenBank
[11], using BioEdit Sequence Alignment Editor Ver.
7.0.5.2 software [12]. Next, we searched for more HBV
variants reported in association with medical and public
health issues (problems in diagnostic assays and/or
escape to vaccine/HBIg therapy) from published articles
and GenBank database, focusing on variants with substi-
tutions at the corresponding amino acid positions.
Totally, an additional 5 sequences were retrieved and
analyzed for their antigenic index calculation.
Prediction of antigenicity
Translated HBsAg sequences that contain mutations
were analyzed with Jameson-Wolf algorithm in the
Lasergene Protean v8.1 program (DNASTAR Inc., Madi-
son, WI) to predict the antigenic index of each consen-
sus sequence. This algorithm integrates several
parameters to calculate the antigenicity of the sequence
based on the characteristics of its primary amino acid
chain: hydrophilicity (Hopp-Woods), surface probability
(Emini), flexibility of the protein backbone (Karplus-
Schulz), and secondary structure prediction (Chou-Fas-
man and Garnier) using the following equation [13]:
A 3 H 15 S 15 F 2 CF 2 RGi i i i i i
i
N
. . . . .= ( ) + ( ) + ( ) + ( ) + ( )
=
∑0 0 0 0 0
1
with regions of positive Ai value clusters indicate pos-
sible antigenic determinants.
Tertiary structure prediction
Based on structural alignment using Template Identifi-
cation tool from Swiss-Model by InterPro Scan,
BLASTP 2.2.9, PSI-BLAST, and HHSEARCH v. 1.5.01
software [14-17], no template structure was found in
ExPDB template library for the 226-amino-acid-long
HBsAg [18]. Therefore, tertiary structures of the HBsAg
variants found in Indonesian blood donor samples were
predicted using free modelling, or often termed as ‘ab
initio’ or ‘de novo’ modelling [19]. In this study, we used
I-TASSER method, a protein structure modelling
approach based on an algorithm consists of consecutive
steps of threading, fragment assembly, and iteration to
obtain structure with the lowest energy as described
previously [20-22]. All structure predictions of wild type
reference sequence and the variants were predicted
separately using individual I-TASSER queries, and visua-
lized using DeepView/Swiss-PdbViewer [23].
Results
Characterization of HBV mutants
Sequencing of partial HBV surface gene of the clones
derived from 25 HBV DNA positive samples [9] showed
nucleotide substitutions in 7 samples: A521G in one
sample, A551T and A562G in one sample, and C582T
in five samples. Of the four nucleotide substitutions,
three single mutation patterns (T123A, M133L and
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T143M) of HBV surface protein were observed, while
A562G was found to be a silent mutation. These muta-
tion positions corresponded with those of five isolates
known to be associated with problem in diagnostic
assays and/or escape to vaccine/HBIg therapy: T123N,
M133I, M133T, M133V, and T143L [5,24-29] (Figure 1).
The remaining 18 (72%) samples did not show any
nucleotide substitutions [9].
Prediction of antigenicity
Prediction of antigenic index of mutant sequences
notably revealed altered antigenicity at and around the
sites of amino acid substitutions compared to the wild
type sequence (Table 1). In T123A substitution, several
amino acids were affected by this single substitution.
Antigenic index values of four amino acids at the
region around amino acid position 123 was altered
between -0.4 to +0.2 in magnitude. In contrast, only a
small antigenicity change was detected (from -0.2 to
-0.05) at the single amino acid site of M133L substitu-
tion. Most significant changes were observed in the
T143M substitution. In this last pattern, antigenic
index of the residues at position 143 and up to 5
amino acids both upstream and downstream of this
site were observed to be altered between -1.07 to
+0.62 in magnitude. These antigenic index changes
were grouped into collectively negative alterations - i.e.
more hydrophobic characteristics - upstream of the
Met at 143, and relatively positive or more hydrophilic
downstream. In comparison, T123N and M133I/V/T
missed in diagnostic assays presented more altered
antigenic index profiles, while T143L showed similar if
not lesser degree of changes (Table 1).
Tertiary structure prediction
The tertiary structure prediction of each variant isolated
from Indonesian blood donors differed slightly from the
wild type reference sequence, particularly in the ’a’
determinant region (Figure 2). The structure of the
mainframe, which consisted mainly of helical structures,
tended to be retained in all sequences, while the loop
structures, including the ’a’ determinant, tended to differ
slightly between these sequences. In pattern T123A, the
loop containing the ’a’ determinant seemed to shift
slightly compared to the reference wild-type. Although
the side chain of Ala did not differ much in its orienta-
tion and position, the remainder of the loop shifted
noticeably, as could be seen in the difference of the coil-
ing and bends of the loop that made the contour of the
’a’ determinant against the cavity in the mainframe
helices. Similar shift in loop structure was observed in
pattern M133L, as could be shown in the different
orientation of Leu side chain in position 133 compared
to Met side chain in the wild-type. The pattern T143M,
on the other hand, besides showing differentially-
oriented side chain of Met, also showed significant
changes in larger part of the loop. Larger region of the
loop N-terminally of position 143 seemed to uncoil,
while the loop positioned C-terminally of residue 143
bent closer toward the mainframe cavity compared to
the reference structure.
Discussion
HBV mechanism of replication includes an RNA inter-
mediate that is reverse-transcribed into DNA by error-
prone RNA polymerase [30]. This process results in a
high mutation rate of approximately 1.4-3.2 × 10-5
Figure 1 Alignment of amino acid sequences of HBV isolates in Indonesian blood donors with frequently-reported variants associated
with failure of diagnostic assays. Three amino acid substitutions were identified in 7 HBV isolates in blood donors: Pattern 1, T123A, in one
isolate; Pattern 2, M133L, in one isolate; Pattern 3, T143M, in five isolates. HBV DNA isolated from the remaining 18 samples showed wild type
(wt) sequences with no amino acid substitution. Consensus of each of the three single mutation patterns and wt were aligned with five known
variants frequently associated with problems in diagnostic assays and/or escape to vaccine/HBIg therapy: T123N, M133I, M133T, M133V, and
T143L, together with M54923 sequence (genotype B/adw) retrieved from GenBank as a reference.
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Table 1 The Jameson-Wolf antigenicity index prediction of HBsAg within amino acid 118 – 160



















110 Ile -0.2 Ile -0.2 Ile -0.2 Ile -0.2 Ile -0.2 Ile -0.2 Ile -0.2 Ile -0.2 Ile -0.2
111 Pro -0.05 Pro -0.05 Pro -0.05 Pro -0.05 Pro -0.05 Pro -0.05 Pro -0.05 Pro -0.05 Pro -0.05
112 Gly 0.35 Gly 0.35 Gly 0.35 Gly 0.35 Gly 0.35 Gly 0.35 Gly 0.35 Gly 0.35 Gly 0.35
113 Ser 0.8 Ser 0.8 Ser 0.8 Ser 0.8 Ser 0.8 Ser 0.8 Ser 0.8 Ser 0.8 Ser 0.8
114 Ser 1 Ser 1 Ser 1 Ser 1 Ser 1 Ser 1 Ser 1 Ser 1 Ser 1
115 Thr 0.4 Thr 0.4 Thr 0.4 Thr 0.4 Thr 0.4 Thr 0.4 Thr 0.4 Thr 0.4 Thr 0.4
116 Thr 1.05 Thr 1.05 Thr 0.8 Thr 1.05 Thr 1.05 Thr 1.05 Thr 1.05 Thr 1.05 Thr 1.05
117 Ser 1.3 Ser 1.3 Ser 1.05 Ser 1.3 Ser 1.3 Ser 1.3 Ser 1.3 Ser 1.3 Ser 1.3
118 Thr 1.2 Thr 1.2 Thr 0.95 Thr 1.2 Thr 1.2 Thr 1.2 Thr 1.2 Thr 1.2 Thr 1.2
119 Gly 2.05 Gly 2.05 Gly 1.6 Gly 2.05 Gly 2.05 Gly 2.05 Gly 2.05 Gly 2.05 Gly 2.05
120 Pro 2.5 Pro 2.5 Pro 2.05 Pro 2.5 Pro 2.5 Pro 2.5 Pro 2.5 Pro 2.5 Pro 2.5
121 Cys 2.25 Cys 2.25 Cys 2.5 Cys 2.25 Cys 2.25 Cys 2.25 Cys 2.25 Cys 2.25 Cys 2.25
122 Lys 2 Lys 1.6 Lys 2.25 Lys 2 Lys 2 Lys 2 Lys 2 Lys 2 Lys 2
123 Thr 0.35 Ala 0.4 Asn 2 Thr 0.35 Thr 0.35 Thr 0.35 Thr 0.35 Thr 0.35 Thr 0.35
124 Cys 0.25 Cys 0.15 Cys 1.5 Cys 0.25 Cys 0.25 Cys 0.25 Cys 0.25 Cys 0.25 Cys 0.25
125 Thr 0.45 Thr 0.65 Thr 0.9 Thr 0.45 Thr 0.45 Thr 0.45 Thr 0.45 Thr 0.45 Thr 0.45
126 Thr 0.25 Thr 0.25 Thr 0.25 Thr 0.25 Thr 0.25 Thr 0.25 Thr 0.25 Thr 0.25 Thr 0.25
127 Pro 0.4 Pro 0.4 Pro 0.4 Pro 0.4 Pro 0.4 Pro 0.4 Pro 0.4 Pro 0.4 Pro 0.4
128 Ala 0.8 Ala 0.8 Ala 0.8 Ala 0.8 Ala 0.8 Ala 0.8 Ala 0.8 Ala 0.8 Ala 0.8
129 Gln 0.8 Gln 0.8 Gln 0.4 Gln 0.8 Gln 0.8 Gln 0.8 Gln 0.8 Gln 0.8 Gln 0.8
130 Gly 0.65 Gly 0.65 Gly 0.65 Gly 0.65 Gly 0.25 Gly 0.8 Gly 0.25 Gly 0.65 Gly 0.65
131 Thr 0.35 Thr 0.35 Thr 0.35 Thr 0.35 Thr -0.05 Thr 0.35 Thr -0.05 Thr 0.35 Thr 0.35
132 Ser 0.35 Ser 0.35 Ser 0.35 Ser 0.35 Ser -0.05 Ser 0.65 Ser -0.05 Ser 0.35 Ser 0.35
133 Met -0.2 Met -0.2 Met -0.2 Leu -0.05 Ile -0.6 Thr 0.8 Val -0.45 Met -0.2 Met -0.2
134 Phe -0.2 Phe -0.2 Phe -0.2 Phe -0.2 Phe -0.2 Phe -0.05 Phe -0.2 Phe -0.2 Phe -0.2
135 Pro 0.2 Pro 0.2 Pro 0.2 Pro 0.2 Pro 0.2 Pro 0.35 Pro 0.2 Pro 0.2 Pro 0.2
136 Ser 0.2 Ser 0.2 Ser 0.2 Ser 0.2 Ser 0.2 Ser 0.2 Ser 0.2 Ser 0.2 Ser 0.2
137 Cys 0.2 Cys 0.2 Cys 0.2 Cys 0.2 Cys 0.2 Cys 0.2 Cys 0.2 Cys 0.2 Cys 0.2
138 Cys 0.64 Cys 0.64 Cys 0.64 Cys 0.64 Cys 0.64 Cys 0.64 Cys 0.64 Cys 0.3 Cys 0.3
139 Cys 1.18 Cys 1.18 Cys 1.18 Cys 1.18 Cys 1.18 Cys 1.18 Cys 1.18 Cys 0.5 Cys 0.8
140 Thr 1.27 Thr 1.27 Thr 1.27 Thr 1.27 Thr 1.67 Thr 1.27 Thr 1.27 Thr 0.41 Thr 0.7
141 Lys 2.36 Lys 2.36 Lys 2.36 Lys 2.36 Lys 2.36 Lys 2.36 Lys 2.36 Lys 1.47 Lys 1.75














Table 1 The Jameson-Wolf antigenicity index prediction of HBsAg within amino acid 118 – 160 (Continued)
143 Thr 2.86 Thr 2.86 Thr 2.86 Thr 2.86 Thr 2.86 Thr 2.86 Thr 2.86 Met 2.74 Leu 3
144 Asp 2.57 Asp 2.57 Asp 2.57 Asp 2.57 Asp 2.57 Asp 2.57 Asp 2.57 Asp 3.1 Asp 2.45
145 Gly 1.93 Gly 1.93 Gly 1.93 Gly 1.93 Gly 1.93 Gly 1.93 Gly 1.93 Gly 2.49 Gly 2.15
146 Asn 1.59 Asn 1.59 Asn 1.59 Asn 1.59 Asn 1.59 Asn 1.59 Asn 1.59 Asn 1.58 Asn 1.25
147 Cys 0.1 Cys 0.1 Cys 0.1 Cys 0.1 Cys 0.1 Cys 0.1 Cys 0.1 Cys 0.72 Cys 0.4
148 Thr -0.6 Thr -0.6 Thr -0.6 Thr -0.6 Thr -0.6 Thr -0.6 Thr -0.6 Thr -0.29 Thr -0.6
149 Cys -0.6 Cys -0.6 Cys -0.6 Cys -0.6 Cys -0.6 Cys -0.6 Cys -0.6 Cys -0.6 Cys -0.6
150 Ile -0.6 Ile -0.6 Ile -0.6 Ile -0.6 Ile -0.6 Ile -0.6 Ile -0.6 Ile -0.6 Ile -0.6
151 Pro -0.6 Pro -0.6 Pro -0.6 Pro -0.6 Pro -0.6 Pro -0.6 Pro -0.6 Pro -0.6 Pro -0.6
152 Ile -0.45 Ile -0.45 Ile -0.45 Ile -0.45 Ile -0.45 Ile -0.45 Ile -0.45 Ile -0.45 Ile -0.45
153 Pro -0.05 Pro -0.05 Pro -0.05 Pro -0.05 Pro -0.05 Pro -0.05 Pro -0.05 Pro -0.05 Pro -0.05
154 Ser 0.35 Ser 0.35 Ser 0.35 Ser 0.35 Ser 0.35 Ser 0.35 Ser 0.35 Ser 0.35 Ser 0.35
155 Ser 0.35 Ser 0.35 Ser 0.35 Ser 0.35 Ser 0.35 Ser 0.35 Ser 0.35 Ser 0.35 Ser 0.35
156 Trp -0.2 Trp -0.2 Trp -0.2 Trp -0.2 Trp -0.2 Trp -0.2 Trp -0.2 Trp -0.2 Trp -0.2
157 Ala -0.6 Ala -0.6 Ala -0.6 Ala -0.6 Ala -0.6 Ala -0.6 Ala -0.6 Ala -0.6 Ala -0.6
158 Phe -0.6 Phe -0.6 Phe -0.6 Phe -0.6 Phe -0.6 Phe -0.6 Phe -0.6 Phe -0.6 Phe -0.6
159 Ala -0.6 Ala -0.6 Ala -0.6 Ala -0.6 Ala -0.6 Ala -0.6 Ala -0.6 Ala -0.6 Ala -0.6
160 Lys -0.6 Lys -0.6 Lys -0.6 Lys -0.6 Lys -0.6 Lys -0.6 Lys -0.6 Lys -0.6 Lys -0.6
*Variants found in Indonesian blood donor; **Variants frequently associated with problems in diagnostic assays and/or escape to vaccine/HBIg therapy. Residues with substitutions and their positions are shown in
bold. Altered antigenicity index of affected residues in each substitution pattern are shown in bold and italics: T123A alters four consecutive residues (aa 122-125); M133L alters the antigenic index of position 133
only; T123N, M133I/T/V, and T143L cause relatively extensive antigenic index changes in 11, 5, 5, 4, and 10 residues, respectively; T143 M shows the most significant changes in the antigenic profile of HBsAg














substitutions/site/year for the whole genome and even
higher for the surface gene [30,31]. This allows the virus
to evolve within a chronically infected individual to
form a naturally occurring quasi-species pool of HBV
variants [5,29]. In regions with high HBV endemicity,
the relatively high rate of viral transmission might pro-
vide more opportunities for super-infection and multiple
infections to occur, which would result in increased
number of variants circulating within individuals as well
as in the population [2,32]. The composition of variants
in the viral population is maintained by its environment.
Variants better suited to the host environment would
prevail and dominate the population [33]. In such cases,
environmental changes induced by either natural
immune response, vaccine-induced or therapeutic
immunoglobulin (HBIg), or even anti-viral therapy may
select for variants that can evade these protective mea-
sures, particularly those exhibiting mutation-induced
conformational changes at the antigenic ’a’ determinant
of its surface antigen [2,3,5]. Selection of variants is
usually indicated by certain serological markers, such as
isolated anti-HBc, co-occurrence of both HBsAg and
anti-HBs, and inconsistent HBsAg assay results [34].
The presence of these variants poses potential threat to
the success of vaccination and supply of safe blood
products due to the possible evasion from vaccine-
generated antibody and poor detection by the available
diagnostic assays [6].
Numerous studies have shown that three dimensional
conformations of proteins contribute toward their biolo-
gical functions as well as their interactions with other
molecules [35,36]. Substitutions of key amino acid resi-
dues may affect the stability and structure of a protein,
altering its properties and interactions with other parti-
cles. Protein modelling of HBsAg variants might give
insight into the structural basis of HBV variation at the
molecular level, and how it affects the HBsAg recogni-
tion by its specific antibody.
Substitutions of Thr 123, Met 133 and Thr 143 into
other amino acid residues as found in this study had
been described in relation to failure of HBIg therapy
and problems in detection assays [5,24-29,37,38]. The
outcome of these substitutions is related to the site of
mutation and the property of the respective amino
acid, which is also observed in the mutants found in
this study. Thr123, although located upstream of the
’a’ determinant, is in close proximity to the Cys 124
residue responsible for maintaining the integrity of
HBsAg antigenic loop. There had been reports of
insertions between Cys residues 121 and 124 that
reduced or abolished bindings by monoclonal antibo-
dies [39,40]. Furthermore, in a study by Chen et al.,
the preservation of Thr at residue 123 seemed to be an
important factor in the recognition of one of the ’a’
determinant epitopes by monoclonal anti-HBs [7].
Hence, the substitution site is important because it
may disturb the disulphide bonds, leading to the
alteration of loop conformation and decrease or loss of
neutralizing antibody binding.
The other two mutation sites, Met 133 and Thr 143, are
located within the first (aa 124-137) and second (aa 139-
147) antigenic loops of the ’a’ determinant, respectively
[7,8,41]. Ample reports on substitutions within these two
regions had been published [5,24,26,27,37,40-43], as the ’a’
determinant is known as the main antibody recognition
site of HBsAg. Mutations at these regions would
Figure 2 Comparison of tertiary structure prediction. Tertiary structure prediction of M54923 (reference sequence), T123A, M133L, and T143M
mutants. The ’a’ determinant is shown in blue, yellow, magenta, and green, respectively, while residues of importance are labelled with the side
chains shown.
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predictably affect the loop conformation and causes pro-
blems of escape mutants and diagnostic failure.
As of the property of each amino acid, protein is a
macromolecule made of monomeric amino acids. Each
amino acid has distinct properties attributable to its
side-chain, and the structure of a protein is dependent
on the composition of its amino acids [44]. Therefore,
differences in amino acid properties might contribute to
the changes in the structure of the ’a’ determinant loop.
Methionine, Alanine, Leucine, Isoleucine, and Valine
are amino acids with non-polar, aliphatic side chains,
while Threonine and Aspargine have a polar although
uncharged side chain (-CH(CH3)-OH and -CH2-CO-
NH2 groups). Within the non-polar, aliphatic amino
acids themselves, there are differences in the length and
bulkiness of the side chain; alanine has a methyl group
(-CH3), valine with iso-propyl group (-CH(CH3)-CH3),
leucine with iso-butyl group (-CH2-CH(CH3)-CH3), iso-
leucine with 2°-butyl group (-CH(CH3)- CH2-CH3) and
methionine with a methyl-ethyl-sulphide group (-CH2-
CH2-S-CH3). These slight differences in the amino acid
properties may affect the tertiary structure of the pro-
tein, as different polarity determines the hydrophobicity
of the residue, while differences in length and bulkiness
of the side chain may influence the steric hindrance
between neighbouring residues [44].
The degree of changes in antigenicity profile was high-
est in pattern T143M , followed closely by T123N and
T143L, then lesser changes in M133I/T/V as well as
T123A and M133L. M133L mutant showed the least
significant changes, probably because it is located in
less-antigenic first loop [41], and also because both Met
and Leu are non-polar residues with similar bulkiness of
their side-chains. T123A mutant, on the other hand,
involved changes from a polar Thr into a non-polar and
slightly smaller Ala. Although it may affect the confor-
mation by means of influencing the disulphide bond,
the effect would be minimized because of the nature
and size of Ala. The trend in M133I/T/V can also be
correlated with the differential amino acid properties,
with similar changes between M133I and M133V that
involve similarly-sized non polar Met, Ile, and Val; and
slightly more significant antigenic alteration in M133T,
in which there is a change from Met to polar Thr.
Marked changes were also observed in T123N and
T143L substitutions, which might be caused by both the
shift from slightly small, polar Thr into either larger,
more polar Asp or bulkier, non-polar Leu and the
importance of their respective locations. Similarly, in
T143M mutation, a major change from polar Thr into
non-polar, significantly bulkier Met within the more
antigenic second loop of the ’a’ determinant occurred
[41]. This is also seen when several of the substitution
patterns were constructed in tertiary structure modelling
(Figure 2), with more significant changes observed if the
amino acids involved had higher degree of variation in
their properties.
Comparison of variants T123A, M133L and T143M
with the reference wild-type HBsAg showed different
predicted tertiary structures with lesser degree of
changes observed in the mainframe helices compared to
the loops’ structures (Figure 2). This might be caused by
the higher degree of freedom in the movement of the
loop regions. Loop regions tend to be hydrophilic and
interact more freely with the surrounding environment,
while mainframe helices are much more constrained in
structure due to the hydrophobicity and tendency to
maintain the distance between their residues [44].
All these observations were obtained by mathematical
model and prediction software, involving various algo-
rithms to calculate the antigenic index and methods to
predict variant HBsAg conformation. Further analysis
involving experimental studies of the interaction
between variant HBsAg and anti-HBs is needed to con-
firm these preliminary findings, and continuous screen-
ing of larger sets of samples is necessary to obtain more
data on the emergence of new variants that might circu-
late in the population.
Conclusions
In conclusion, antigenic index analysis and de novo
prediction of tertiary conformation of the three HBsAg
variants (T123A, M133L, and T143M) found in Indone-
sian blood donor samples with undetectable HBsAg
revealed that T143M substitution altered the antigeni-
city most significantly compared to the other two muta-
tion patterns and the other known variants. This finding
offers insight into the possibility of predicting antigenic
changes in unique variants based on its primary amino
acid sequence. It also underlines the importance of pro-
tein structure prediction in understanding the dynamic
interactions between pathogenic agents and host
immune system, in anticipation of new variants that
might emerge in the future. This would in turn be a
useful tool to better overcome the issues regarding
detection failure by diagnostic assays and the global use
of vaccines, particularly in endemic areas, as one possi-
ble mechanism of selecting escape mutants.
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